Literature DB >> 12829813

Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection.

Viviana Simon1, Neal Padte, Deya Murray, Jeroen Vanderhoeven, Terri Wrin, Neil Parkin, Michele Di Mascio, Martin Markowitz.   

Abstract

It is believed that replication capacity is an important determinant of human immunodeficiency virus type 1 (HIV-1) pathogenicity and transmissibility. To explore this, we conducted a comprehensive analysis of the replication properties of nine drug-resistant and nine drug-susceptible viral isolates derived from patients with primary HIV-1 infection. Viral isolates were tested for single-cycle infectivity in the GHOST cell line. The infectivity of isolates carrying resistance-associated mutations was significantly higher than that of drug-susceptible isolates. Additionally, the growth kinetics of these isolates were determined in CD4+ T lymphocytes. Drug-resistant isolates replicated as well as drug-susceptible viruses. Insertion of the resistance-conferring regions into an NL4-3-based molecular background resulted in chimeras that displayed a modest but significant reduction in replication capacity compared to the drug-susceptible chimeric viruses. Of note, two multidrug-resistant isolates and one protease inhibitor-resistant isolate displayed higher rates of infectivity and growth kinetics than the other drug-resistant or drug-susceptible isolates. These distinct replicative features, however, were not seen in the corresponding chimeras, indicating that changes within the C-terminal region of Gag as well as within the protease and reverse transcriptase genes contribute to but are not sufficient for the level of compensatory adaptation observed. These findings suggest that some drug-resistant viruses isolated during primary infection possess unique adaptive changes that allow for both high viral replication capacity and resistance to one or more classes of antiretroviral drugs. Further studies are needed to elucidate the precise regions that are essential for these characteristics.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12829813      PMCID: PMC161921          DOI: 10.1128/jvi.77.14.7736-7745.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease.

Authors:  Deborah S Dauber; Rainer Ziermann; Neil Parkin; Dustin J Maly; Sami Mahrus; Jennifer L Harris; Jon A Ellman; Christos Petropoulos; Charles S Craik
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

2.  Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy.

Authors:  H M Precious; H F Günthard; J K Wong; R T D'Aquila; V A Johnson; D R Kuritzkes; D D Richman; A J Leigh Brown
Journal:  AIDS       Date:  2000-01-07       Impact factor: 4.177

3.  Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study.

Authors:  H Salomon; M A Wainberg; B Brenner; Y Quan; D Rouleau; P Coté; R LeBlanc; E Lefebvre; B Spira; C Tsoukas; R P Sekaly; B Conway; D Mayers; J P Routy
Journal:  AIDS       Date:  2000-01-28       Impact factor: 4.177

4.  Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants.

Authors:  C Dykes; K Fox; A Lloyd; M Chiulli; E Morse; L M Demeter
Journal:  Virology       Date:  2001-07-05       Impact factor: 3.616

5.  Founder virus population related to route of virus transmission: a determinant of intrahost human immunodeficiency virus type 1 evolution?

Authors:  V V Lukashov; J Goudsmit
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

6.  Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy.

Authors:  A J Hance; V Lemiale; J Izopet; D Lecossier; V Joly; P Massip; F Mammano; D Descamps; F Brun-Vézinet; F Clavel
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

7.  Reduced antiretroviral drug susceptibility among patients with primary HIV infection.

Authors:  S J Little; E S Daar; R T D'Aquila; P H Keiser; E Connick; J M Whitcomb; N S Hellmann; C J Petropoulos; L Sutton; J A Pitt; E S Rosenberg; R A Koup; B D Walker; D D Richman
Journal:  JAMA       Date:  1999 Sep 22-29       Impact factor: 56.272

8.  Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein.

Authors:  S Peters; M Muñoz; S Yerly; V Sanchez-Merino; C Lopez-Galindez; L Perrin; B Larder; D Cmarko; S Fakan; P Meylan; A Telenti
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

9.  Impaired replication of protease inhibitor-resistant HIV-1 in human thymus.

Authors:  C A Stoddart; T J Liegler; F Mammano; V D Linquist-Stepps; M S Hayden; S G Deeks; R M Grant; F Clavel; J M McCune
Journal:  Nat Med       Date:  2001-06       Impact factor: 53.440

10.  Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage.

Authors:  A Mörner; A Björndal; J Albert; V N Kewalramani; D R Littman; R Inoue; R Thorstensson; E M Fenyö; E Björling
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

View more
  18 in total

1.  Density-dependent selection in vesicular stomatitis virus.

Authors:  Isabel S Novella; Daniel D Reissig; Claus O Wilke
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

2.  The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity.

Authors:  Marcel Ooms; Susan Majdak; Christopher W Seibert; Ariana Harari; Viviana Simon
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

Review 3.  Minority variants of drug-resistant HIV.

Authors:  Sara Gianella; Douglas D Richman
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

4.  Viral envelope is a major determinant of enhanced fitness of a multidrug-resistant HIV-1 variant.

Authors:  Hiroshi Mohri; Nicole Prada; Martin Markowitz
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

5.  Prevalence of primary resistance at baseline in acutely and recently infected subjects enrolled in AIDS clinical trials group protocol 371.

Authors:  Carrie Dykes; A Lisa Mukherjee; Ronald J Bosch; Elizabeth Connick; Paul A Volberding; Lisa M Demeter
Journal:  J Acquir Immune Defic Syndr       Date:  2010-09       Impact factor: 3.731

6.  Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture.

Authors:  Marco Petrella; Maureen Oliveira; Daniela Moisi; Mervi Detorio; Bluma G Brenner; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

7.  Transmission cluster of multiclass highly drug-resistant HIV-1 among 9 men who have sex with men in Seattle/King County, WA, 2005-2007.

Authors:  Susan E Buskin; Giovanina M Ellis; Gregory G Pepper; Lisa M Frenkel; Steven A Pergam; Geoffrey S Gottlieb; Carrie Horwitch; Jeffrey F Olliffe; Karen Johnson; Peter Shalit; Corinne Heinen; Margot Schwartz; Robert W Wood
Journal:  J Acquir Immune Defic Syndr       Date:  2008-10-01       Impact factor: 3.731

8.  Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1.

Authors:  Haili Zhang; Yan Zhou; Cecily Alcock; Tara Kiefer; Daphne Monie; Janet Siliciano; Quan Li; Paul Pham; Joseph Cofrancesco; Deborah Persaud; Robert F Siliciano
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

9.  In vitro characterization of multidrug-resistant HIV-1 isolates from a recently infected patient associated with dual tropism and rapid disease progression.

Authors:  Hiroshi Mohri; Martin Markowitz
Journal:  J Acquir Immune Defic Syndr       Date:  2008-08-15       Impact factor: 3.731

10.  Replication and drug resistant mutation of HIV-1 subtype B' (Thailand B) variants isolated from HAART treatment individuals in China.

Authors:  Jianping Sun; Liying Ma; Xiaoling Yu; Yang Huang; Lin Yuan; Yiming Shao
Journal:  Virol J       Date:  2009-11-18       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.